Ocugen with ticker code (OCGN) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 1 and 0.7 with the average target price sitting at 0.9. Now with the previous closing price of 0.29 this would imply there is a potential upside of 210.3%. The 50 day MA is 0.31 and the 200 day moving average is 0.34. The market capitalisation for the company is $130m. Company Website: http://www.ocugen.com
Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.